Читаем Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний полностью

Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

Бастиан Блоэм , Майкл Окун , Рэй Дорси , Тодд Шерер

58. Parkinson’s Foundation announces new genetic initiative connecting Parkinson’s genetic data with clinical care [пресс-релиз]. Parkinson’s Foundation. March 6, 2018. https://parkinson.org/about-us/Press-Room/ Press-Releases/Parkinsons-Foundation-Announces-New-Genetic-Initiative-Connecting-Parkinsons-Genetic-Data-with-Clinical-Care. Accessed June 27, 2019.

59. Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2-associated Parkinson disease population. JAMA Neurology. 2018;75(3):312–319; Davis MY, Johnson CO, Leverenz JB, et al. Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease. JAMA Neurology. 2016;73(10):1217–1224; Genetics initiative. Parkinson’s Foundation. www.parkinson.org/research/genetics-initiative. Accessed March 29, 2019.

60. CR, Jr. Passive immunization against poliomyelitis: the Hammon gamma globulin field trials, 1951–1953. American Journal of Public Health. 2005;95(5):790–799.

61. Там же.

62. Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-a-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurology. 2018;75(10):1206–1214.

63. Fletcher K. Trials to treatments: vaccines for Parkinson’s. Medium. November 19, 2018. https://medium.com/parkinsons-uk/vaccines-for-parkinsons-b09634c84017. Accessed May 20, 2019.

64. Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-a-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurology. 2018;75(10):1206–1214; Manfredsson FP, Tansey MG, Golde TE. Challenges in passive immunization strategies to treat Parkinson disease. JAMA Neurology. 2018;75(10):1180–1181.

65. AFFiRiS AG. AFFiRiS announces top line results of first-in-human clinical study using AFFITOPE PD03A, confirming immunogenicity and safety profile in Parkinson’s disease patients. Cision PR Newswire. June 7, 2017. www.prnewswire.com/news-releases/affiris-announces-top-line-results-of-first-in-human-clinical-study-using-affitope-pd03a-confirming-immunogenicity-and-safety-profile-in-parkinsons-disease-patients-627025511.html. Accessed June 27, 2019; Affitope PD03A. Parkinsons’s News Today. https://parkinsonsnewstoday.com/ affitope-pd03a. Accessed March 29, 2019.

66. Kuhl MM. Vaccine for Parkinson’s reports positive results from boost study. FoxFeed Blog. September 7, 2016. www.michaeljfox.org/news/ vaccine-parkinsons-reports-positive-results-boost-study. Accessed June 27, 2019.

67. Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316(24):2627–2646.

68. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. New England Journal of Medicine. 2009;361(13):1268–1278; Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Archives of Neurology. 2002;59(12):1937–1943.

69. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. New England Journal of Medicine. 2009;361(13):1268–1278; Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Experimental Neurology. 2004;187(2):455–459.

70. Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Experimental Neurology. 2004;187(2):455–459.

71. 45 million Americans forego medications due to costs, new analysis shows—9 times the rate of the UK [пресс-релиз]. Prescription Justice. February 6 2017. https://prescriptionjustice.org/ press_release/45-million-americans-forego-medications-due-to-costs-new-analysis-shows-9-times-the-rate-of-the-uk. Accessed June 27, 2019.

72. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics. 2016;47:20–33.

73. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Affairs. 2006;25(2):420–428; Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D. The cost of drug development: a systematic review. Health Policy. 2011;100(1):4-17.

Перейти на страницу: